Evolution and mechanisms of cytomegalovirus antagonism of host cell defenses

巨细胞病毒拮抗宿主细胞防御的进化和机制

基本信息

  • 批准号:
    10376227
  • 负责人:
  • 金额:
    $ 44.01万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-04-01 至 2024-03-31
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract Human cytomegalovirus (HCMV) causes life-threatening diseases in patients with poor immune system function and long-lasting neurological disabilities in congenitally-infected newborns. In addition to its medical importance, HCMV and related viruses provide a powerful experimental model for investigating how viruses evolve to elude host cell defense systems. The long-term goal of this research is to discover evolutionary and molecular mechanisms by which viruses like HCMV control the host cell's protein synthesis machinery to allow viral replication. One of the defense systems that inhibits many viruses is mediated by protein kinase R (PKR). HCMV encodes two protein antagonists of PKR, TRS1 and IRS1, at least one of which is absolutely essential for the virus to replicate in human cells. Aim 1 seeks to understand why HCMV, like several other large DNA viruses, has two genes that serve the same function. Studies of mutant viruses that have only one of the genes will be used to determine why viruses lacking TRS1 have a replication defect not observed with viruses lacking just IRS1. Other experiments will reveal whether the combination of both genes confers a benefit to the virus under conditions that more closely model natural infections than previous studies, such as when clinical strains of HCMV infect different types of cells, and when they encounter an inflammatory environment. Aim 2 will elucidate mechanisms by which CMV can adapt to overcome PKR using gene duplication and horizontal gene transfer, two processes that have had major impacts on the evolution of large DNA viruses. Aim 3 will dissect how a domain in PKR that is critical for its activity has adapted to maintain its function in defending the host, while changing enough to evade viral factors. Comparisons of variants of this domain in humans, Old World monkeys, and New World monkeys, using the powerful technique of “deep mutational scanning” in which each amino acid in a protein is mutated to all of the other 19 alternatives, will reveal how this region of PKR has evolved and how in turn CMVs have evolved to adapt to the changes. These studies will reveal insights into the mechanisms and evolution of both viral and host factors that are in conflict and that determine whether the virus replicates or is successfully blocked by host defenses.
项目摘要/摘要 人巨细胞病毒(HCMV)在免疫系统低下的患者中引起危及生命的疾病 先天性感染新生儿的功能和长期神经功能障碍。除了它的医疗保健 重要性,巨细胞病毒及相关病毒为研究病毒如何 进化成躲避宿主细胞防御系统。这项研究的长期目标是发现进化和 巨细胞病毒等病毒控制宿主细胞蛋白质合成机制的分子机制 病毒复制。蛋白激酶R(PKR)是抑制多种病毒的防御系统之一。 人巨细胞病毒编码PKR的两种蛋白拮抗剂TRS1和IRS1,其中至少有一种是绝对必需的 让病毒在人类细胞中复制。Aim 1试图理解为什么HCMV和其他几个大型DNA一样 病毒有两个基因具有相同的功能。只有一种基因的突变病毒的研究 将用于确定为什么缺少TRS1的病毒具有在缺少病毒的情况下没有观察到的复制缺陷 只有IRS1。其他实验将揭示这两种基因的结合是否对病毒有利。 在比以前的研究更接近模拟自然感染的条件下,例如当临床菌株 人巨细胞病毒感染不同类型的细胞,当它们遇到炎症环境时。目标2将 阐明CMV通过基因复制和水平调节克服PKR的机制 基因转移,这两个过程对大型DNA病毒的进化产生了重大影响。目标3将 剖析PKR中对其活动至关重要的结构域如何适应维持其在 保护宿主,同时做出足够多的改变来躲避病毒因素。这一领域的变体的比较 在人类、东半球的猴子和新大陆的猴子中,使用了强大的“深度突变”技术 扫描一种蛋白质中的每一种氨基酸都突变为所有其他19种氨基酸,将揭示这一现象是如何发生的 PKR的区域已经进化,而CMV又是如何进化来适应变化的。这些研究将 揭示病毒和宿主因素的机制和演变,这些因素处于冲突中, 确定病毒是否可以复制或被主机防御系统成功阻止。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ADAM P. GEBALLE其他文献

ADAM P. GEBALLE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ADAM P. GEBALLE', 18)}}的其他基金

Evolution and mechanism of restriction of herpesviruses by MxB
MxB限制疱疹病毒的进化和机制
  • 批准号:
    10667144
  • 财政年份:
    2023
  • 资助金额:
    $ 44.01万
  • 项目类别:
Roles and regulation of polyamines during HCMV infection
多胺在 HCMV 感染过程中的作用和调节
  • 批准号:
    10308688
  • 财政年份:
    2020
  • 资助金额:
    $ 44.01万
  • 项目类别:
Evolution and mechanisms of cytomegalovirus antagonism of host cell defenses
巨细胞病毒拮抗宿主细胞防御的进化和机制
  • 批准号:
    10630815
  • 财政年份:
    2020
  • 资助金额:
    $ 44.01万
  • 项目类别:
Roles and regulation of polyamines during HCMV infection
多胺在 HCMV 感染过程中的作用和调节
  • 批准号:
    10593450
  • 财政年份:
    2020
  • 资助金额:
    $ 44.01万
  • 项目类别:
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection
优化免疫和母体宿主防御先天性巨细胞病毒感染的能力
  • 批准号:
    10434692
  • 财政年份:
    2019
  • 资助金额:
    $ 44.01万
  • 项目类别:
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection
优化免疫和母体宿主防御先天性巨细胞病毒感染的能力
  • 批准号:
    10005407
  • 财政年份:
    2019
  • 资助金额:
    $ 44.01万
  • 项目类别:
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection
优化免疫和母体宿主防御先天性巨细胞病毒感染的能力
  • 批准号:
    10188583
  • 财政年份:
    2019
  • 资助金额:
    $ 44.01万
  • 项目类别:
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection
优化免疫和母体宿主防御先天性巨细胞病毒感染的能力
  • 批准号:
    10626882
  • 财政年份:
    2019
  • 资助金额:
    $ 44.01万
  • 项目类别:
Roles of Experimentally Evolved Vaccinia Mutations in Antagonizing Cell Defenses
实验进化的痘苗突变在拮抗细胞防御中的作用
  • 批准号:
    8848032
  • 财政年份:
    2014
  • 资助金额:
    $ 44.01万
  • 项目类别:
Roles of Experimentally Evolved Vaccinia Mutations in Antagonizing Cell Defenses
实验进化的痘苗突变在拮抗细胞防御中的作用
  • 批准号:
    8769973
  • 财政年份:
    2014
  • 资助金额:
    $ 44.01万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 44.01万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 44.01万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 44.01万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 44.01万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 44.01万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 44.01万
  • 项目类别:
    Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 44.01万
  • 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 44.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 44.01万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 44.01万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了